Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy

Launched by INSTITUTO VALENCIANO DE INFERTILIDAD, IVI VALENCIA · May 21, 2014

Keywords

ClinConnect Summary

This novel technique refers to the use of CD133+ autologous bone marrow stem-cells to regenerate the endometrium in patients with Asherman's Syndrome, Endometrial Atrophy or any condition that produce a destruction of the endometrium or its de novo creation in a bioengineered uterus.

It requires a previous mobilization in the peripheral blood of CD133+ autologous bone marrow stem cells, subsequent apheresis and transplant of the same cells in the spiral arterioles of the uterus with the aim to regenerate de novo the endometrium. This technique represents a new therapeutical approach for th...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed of Asherman Syndrome and absence of pregnancy after treatment
• • Endometrial atrophy (\<6mm) with Implantation Failure
• • Age 20-45 years-old
• • Normal liver, heart and kidney function
• • Presence of menstrual bleeding with Natural Cycle or HRT
• • Absence of psychiatric pathology and ability to accomplish the treatment
• • β-hCG negative
• • Absence of SDT
• Exclusion Criteria:
• • Absence of peripheral vein access
• • Lack of accomplish inclusion criteria